Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Novo Nordisk Seeks to Solidify Its Lead in Diabetes Treatment and Crushing the Market
Novo Nordisk Seeks to Solidify Its Lead in Diabetes Treatment and Crushing the Market
Novo Nordisk Seeks to Solidify Its Lead in Diabetes Treatment and Crushing the Market
Submitted by
admin
on April 6, 2023 - 11:29am
Source:
Motley Fool
News Tags:
Novo Nordisk
diabetes
Ozempic
Rybelsus
Headline:
Novo Nordisk Seeks to Solidify Its Lead in Diabetes Treatment and Crushing the Market
snippet:
Novo Nordisk controls almost one-third of the entire worldwide diabetes market.
Patent protection on Ozempic and Rybelsus, which treat type 2 diabetes and can help with weight loss, lasts until 2032 in the United States.
Net profit of more than $8 billion in 2022 was up 16% in Danish kroner.
Do Not Allow Advertisers to Use My Personal information
